Pharmacovigilance Plan of the EU Regulatory Network for ...
Information on studies that are initiated will be available on the EU PAS Register. 5.5. Spontaneous reporting of suspected adverse reactions The regulatory requirements for the collection, data management and submission of individual reports of suspected adverse reactions associated with medicinal products are addressed in GVP Module VI.
Download Pharmacovigilance Plan of the EU Regulatory Network for ...
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
APPLICATION, SELECTION AND ADMISSION for …
www.sun.ac.za• Applied Medicinal Chemistry ... 2.3.2 The final offer must be accepted to obtain final admission status and permission to register. 2.3.3 Registration can be done electronically online (e-registration) from two weeks prior to the start
CHAPTER 681. MEDICAL MARIJUANA REGULATIONS …
oklahoma.govgeneral and permanent rules published in the Federal Register by the executive departments and agencies of the federal government which is published by the U.S. Government Printing Office. Citations in this Chapter to the CFR refer sequentially to the Title, Part and Section numbers. "
Labelling Requirements for Investigational Medicinal ...
www.dgra.deLabelling is an important and integral part of the approval of a medicinal product. This also applies to the investigational medicinal product (IMP) in clinical trials (CTs). The IMP should be correctly labelled according to the mandatory information required by regulatory authorities. The label has to be permanently affixed to the container.
EMA’S GUIDE ON ADVANCED THERAPY MEDICINAL …
www.ema.europa.euCheck the community register of orphan medicinal products to see if a similar medicinal product for the same therapeutic indication has been granted market exclusivity protection Perform a potency assay study The potency assay has to relate to the mechanism of action and correlate to the clinical outcomes.
School of Health and Social Work Pre-Registration Nursing ...
www.iow.nhs.uk1.1 Student nurses must never administer or supply medicinal products without supervision. 1.2 Throughout their time in clinical practice, all students need to be involved with registered practitioners when administering medicines in a way which provides them with an understanding of the full range of processes involved.